Comparison of the effect of calcium gluconate and batroxobin on the release of transforming growth factor beta 1 in canine platelet concentrates.
Authors: Silva Raul F, Carmona Jorge U, Rezende Cleuza M F
Journal: BMC veterinary research
Summary
# Editorial Summary Platelet-rich plasma (PRP) and other autologous platelet concentrates have become established tools in equine regenerative medicine, yet optimising their therapeutic efficacy requires understanding how activation methods influence the release of key growth factors. Silva and colleagues investigated whether calcium gluconate alone or combined with batroxobin (a snake venom component) produces differential concentrations of transforming growth factor beta 1 (TGF-β1)—a potent anti-inflammatory and tissue-repair mediator—in canine platelet concentrates separated into upper and lower fractions. Using blood samples from 16 dogs, the researchers prepared platelet concentrates, characterised their cellular composition, and measured TGF-β1 release following activation with either calcium gluconate or batroxobin plus calcium gluconate, also examining correlations between cell counts and growth factor concentration. The findings demonstrated that activation method and fraction type both influenced TGF-β1 availability, with batroxobin-calcium combination activation producing notably higher growth factor release than calcium gluconate alone in specific fractions. For equine practitioners employing platelet concentrates in soft tissue and orthopaedic regenerative therapy, these results suggest that activation protocol selection materially affects the biological potency of the final product, warranting consideration of batroxobin-enhanced activation when TGF-β1 bioavailability is a clinical priority, whilst recognising that the canine model may not fully translate to equine physiology.
Read the full abstract on PubMed
Practical Takeaways
- •Activation method (calcium gluconate vs batroxobin) significantly affects growth factor release from platelet concentrates and should be carefully selected based on clinical goals
- •Stratification of platelet concentrates into fractions yields different cellular compositions and potentially different therapeutic properties
- •Monitoring both cell counts and TGF-β1 levels may help optimize platelet concentrate preparation for regenerative therapy applications
Key Findings
- •TGF-β1 concentration differed between calcium gluconate and batroxobin plus calcium gluconate activation methods in canine platelet concentrates
- •Cellular populations varied between lower fraction (PC-A) and upper fraction (PC-B) of platelet concentrates
- •Correlations were established between cell counts in platelet concentrates and TGF-β1 concentrations